3rd CNS Anticancer Drug Discovery and Development Conference
We are pleased to announce that the 3rd CNS Anticancer Drug Discovery and Development Conference (CADDDC) will be held November 14 - 15, 2018 just prior to the SNO Annual Meeting in New Orleans. The Scientific Program Committee has developed a world-class program that will provide an educational venue for scientists, clinicians, and regulatory decision-makers to better understand the special requirements for effective anticancer therapies for the treatment of primary infiltrative gliomas, medulloblastoma, and metastatic tumors to the CNS. The Conference will provide a setting to facilitate discussion of the range of issues that have impacted on the failure to develop unique drugs for CNS cancers as well as innovative approaches being applied to brain tumor chemotherapy. Through this educational and research-oriented conference the goals are to create a dialogue amongst attendees and their collaborators to enhance drug development for primary gliomas, medulloblastoma, and secondary metastatic CNS tumors and, thereby, improve patient outcomes.
Following the first CADDDC in 2014, participants generated a White Paper that was published as a supplement to the journal Neuro-Oncology (https://academic.oup.com/neuro-oncology/article/17/suppl_6/vi1/1087922). The second CADDDS in 2016 led to a publication in CNS Oncology that summarized the Conference (https://www.futuremedicine.com/doi/abs/10.2217/cns-2017-0014). For those contemplating attending this year's CNS Anticancer Drug Discovery and Development Conference, reading these two documents will help you appreciate the breadth and value of these conferences.
Over 20 speakers representing a wide range of academia and industry have been invited to speak at this year's conference. Select abstract presentations will be featured and an evening poster and networking reception will allow attendees the opportunity to discuss their research in a more informal setting.
Click here to view a copy of the preliminary program.
Registration Now Open. Click Here
Government/Academia: early bird $295; after 9/7 $345
Industry: early bird $395; after 9/7 $445
Scientific Program Committee
Victor A. Levin, MD, Chair
Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center
Department of Neurosurgery, UCSF Medical School
James M. Gallo, PharmD, PhD
Department of Pharmaceutical Sciences
University at Buffalo
David J. Odde, PhD
Department of Biomedical Engineering
University of Minnesota
Russell C. Petter, PhD
Founder and Chief Scientific Officer
Zoran Rankovic, PhD
CBT Chemistry Centers
St Jude Children's Research Hospital
Jeremy N. Rich, MD
Department of Medicine
UCSD School of Medicine
Peter J. Tonge, PhD
Departments of Chemistry and Radiology
Stony Brook School of Medicine